LPT 111111- A Single-Arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE) and Lapatinib (TYKERB) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer.

Trial Profile

LPT 111111- A Single-Arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE) and Lapatinib (TYKERB) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 12 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 10 Jan 2018 Planned End Date changed from 1 Dec 2017 to 31 Dec 2018.
    • 07 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top